Company Profile Boehringer Ingelheim Group ranks among the top 20 in the world and is a leading pharmaceutical company highly driven by R&D. Its core business includes prescription drugs, independent health products, animal health and biopharmaceuticals, and its business scope covers all parts of the country. Major provinces, cities and regions.
Boehringer Ingelheim’s main research areas include: immune and respiratory diseases, cardiovascular and metabolic diseases, central nervous diseases, and tumors. In 2014 net sales, prescription drugs accounted for 76% of the group's net sales. The company's best-selling prescription drugs include SPIRIVA, PITAQUAN, MICASO and COBIT.
Boehringer Ingelheim ranks sixth in the global independent health care products market. In 2014, the sales of independent health care drugs accounted for 11% of the group's net sales. The company's four core products of independent health care drugs are Beisupin, Lecosu, Mucotropin and Fuma.
In addition, Boehringer Ingelheim is also the fastest growing animal health business supplier in the world. In 2014, the animal health business accounted for 8% of the company's total sales.
Another strong-growing business of the company is biopharmaceuticals, accounting for 5% of total net sales. Major projects include contract manufacturing and research and development of new biological drugs (NBEs). Its production sites in Bibrach, Germany, Vienna, Austria, California, USA, and Shanghai, China develop and produce biopharmaceuticals through cell culture or microbial and yeast fermentation. Boehringer Ingelheim has a complete biopharmaceutical industry chain, from genetic engineering of cells to manufacturing, and commercial production of off-the-shelf medicines for external industrial customers. R&D Technology In 2014, the company invested 2.654 billion euros in R&D, and the R&D expenses of the prescription drug business accounted for 23.5% of the total prescription drug sales. Boehringer Ingelheim has a global R&D network, with its main R&D centers located in Germany (Biberach and Ingelheim), the United States (Ritchfield), Austria (Vienna), Milan, Italy, and Kobe, Japan.
In 2014, Boehringer Ingelheim submitted marketing authorization applications for a large number of compounds, and the approval and launch of many new drugs will continue to drive the company's future growth. The company's successfully launched new drugs include STRIVERDI Respimat for chronic obstructive pulmonary disease (COPD); JARDIANCE for the treatment of type 2 diabetes and GLYXAMBI whose active ingredients are a combination of linagliptin and empagliflozin; the treatment of idiopathic pulmonary disease OFEV for fibrosis (IPF) and VARGATEF, which was launched in early January 2015 for the treatment of patients with advanced lung adenocarcinoma after chemotherapy.
In 2014, Boehringer Ingelheim conducted about 100 clinical studies, involving more than 100,000 patients, covering tumors, psychiatric diseases, psoriasis, and spondyloarthritis. and Crohn's disease and idiopathic pulmonary fibrosis.